Is it safe to use erythromycin during pregnancy?

It is generally considered to be safe to use erythromycin during pregnancy because there is a minimum risk of harmful effects on the developing fetus. Erythromycin is placed in pregnancy category B by food and drug management (FDA), which means that testing of erythromycin animals during pregnancy did not detect any significant risk to the fetus. Although no fully controlled human studies were carried out, no significant teratogenic or harmful abnormal effects were found in humans. However, it was found that using a specific form of erythromycin called erythromycin estolate during pregnancy increases the possibility of hepatotoxicity or liver damage or liver damage, and should only be used when a clear need has been proven. In this study, no harmful or teratogenic effects were observed, although rats received erythromycin for the whole mating process, as well as during pregnancy and weaning. This evidence promotes the safety of erythromycin, but cannot be fully used on humans.

Several supervisory studies have observed different pregnancies and recorded the safety data of the use of erythromycin during pregnancy. One study, a collaborative perinatal project, observed 230 pregnancies in which the developing fetus was exposed to erythromycin, out of a total of 50 282 pregnancies. No major link between erythromycin during pregnancy and main developmental problems was observed.

Another supervision study, which monitored 229 101 pregnancies of patients receiving Medicaid in Michigan, found 6,972 cases of erythromycin use during pregnancy. 320 main congenital defects were observed from these pregnancies. While this number is slightly higher than the expected diameter of 297 defects, the study did not detect a signicant of correlation between the use of erythromycin and the resulting congenital defects.

erythromycin crosses the placental barrier and enters the blood in the fetus in a small mnlines. Although the levels of erythromycin increase in the fetal bloodstream when the mother's dosage increases, the levels of the mother's erythromycin may change during pregnancy, making it difficult to measure the degree of transmission. The levels in the fetal bloodstream are generally considered to be sufficiently low in order not to cause harmful effects.

During pregnancy, erythromycin erythromycin, erythromycin estolate should not be used. It has been found to increase serum glutamical-oxaloacetic transaminase (SGOT) levels in the bloodstream when taken during the second trimester of pregnancy. In one study, 10% of patients experienced these elevated SGOT levels, which indicates hepatotoxy. Once the use of erythromycin has been stopped, these levels have returned to normal, indicating that it is a temporary side of the drug.